Personalis, Inc. to Present at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2019
25 10월 2019 - 12:00AM
Business Wire
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics
for cancer, today announced that the company will participate in
the AACR-NCI-EORTC International Conference on Molecular Targets
and Cancer Therapeutics 2019 in Boston, October 27-30, including a
poster presentation on October 27th.
The poster presentation, titled “A comprehensive, highly
accurate genomics platform for precision immunotherapy:
Simultaneously characterize tumors and the TME from a single FFPE
sample,” will describe the Personalis universal cancer
immunogenomics platform, ImmunoID NeXT™. The poster will provide an
overview of how the platform can be used to explore critical
immunotherapy-related biomarkers of resistance and response;
utilizing analytics including: human leukocyte antigen (HLA) typing
and HLA loss of heterozygosity (LOH), neoantigen prediction and
load, immune repertoire characterization, oncoviral detection,
immune cell deconvolution, as well as the evaluation of tumor
mutational burden (TMB) and microsatellite instability (MSI)
status.
ImmunoID NeXT™ is the first platform to enable comprehensive
analysis of both a tumor and its immune microenvironment from a
single sample. The platform can be used to investigate the key
tumor- and immune-related areas of cancer biology, consolidating
multiple oncology biomarker assays into one and maximizing the
biological information that can be generated from a precious tumor
specimen.
The presentation will be delivered by Robert Power, M.S.,
Product Manager.
About Personalis, Inc.
Personalis, Inc. is a growing cancer genomics company
transforming the development of next-generation therapies by
providing more comprehensive molecular data about each patient’s
cancer and immune response. The company’s NeXT™ Platform is
designed to adapt to the complex and evolving understanding of
cancer, providing its biopharmaceutical customers with information
on all of the approximately 20,000 human genes, together with the
immune system, from a single tissue sample. Personalis also
provides genomic information to the VA Million Veterans Program as
part of their goal to sequence over a million veteran genomes. The
Personalis Clinical Laboratory is GxP aligned as well as
CLIA’88-certified and CAP-accredited. For more information, please
visit www.personalis.com and follow Personalis on Twitter
(@PersonalisInc).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191024005302/en/
Investor Relations Contact for Personalis: Caroline Corner
investors@personalis.com www.westwicke.com 415-202-5678
Media Contact for Personalis: Jennifer Havlek pr@personalis.com
www.personalis.com 650-752-1300
Personalis (NASDAQ:PSNL)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Personalis (NASDAQ:PSNL)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024